| abstract |
PROBLEM TO BE SOLVED: To inhibit protease and to associate with harmful protease activity in gastrointestinal fistula such as dyspepsia, gastritis, gastric ulcer, gastroesophageal reflux disease, throat laryngeal acid reflux disease, irritable bowel syndrome, rectal related inflammatory disease, inflammatory bowel disease, etc. And a pharmaceutical composition containing the substance useful for the disease. A silica that inhibits protease and a pharmaceutical composition containing the silica. The silica is preferably selected from the group consisting of fumed silica, precipitated silica, amorphous silica, coacervate silica, amorphous silica gel, silica sol, hydrogel silica, and xerogel silica. In particular, the silica preferably has an average particle diameter (d50) of 10 to 80 nm and a surface area of 5 to 350 m 2 / g. The silica is preferably in the state of a suspending agent. [Selection] Figure 1 |